Education
About Us
Working with TipRanks
Follow Us
Else Nutrition Holdings Inc (TSE:BABY)
TSX:BABY
Top Page
Else Nutrition Holdings Inc
(TSX:BABY)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.00
▼(-100.00% Downside)
Else Nutrition Holdings Inc faces substantial financial challenges, with declining revenues and negative profitability metrics being the most significant concerns. While technical indicators suggest stability, the negative P/E ratio and lack of dividends weaken the stock's valuation appeal. The earnings call provided some positive insights into cost management and strategic growth initiatives, but these are overshadowed by ongoing financial struggles.
Else Nutrition Holdings Inc (BABY) vs. iShares MSCI Canada ETF (EWC)
Market Cap
$7.48M
Dividend YieldN/A
Average Volume (3M)287.16K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth-22.92%
EPS Growth39.22%
CountryCA
Employees32
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)N/A
Shares Outstanding374,114,300
10 Day Avg. Volume861,485
30 Day Avg. Volume287,161
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue0.72
Enterprise Value/Gross Profit-2.99
Enterprise Value/Ebitda-0.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Else Nutrition Holdings Inc Business Overview & Revenue Model
Company DescriptionElse Nutrition Holdings Inc. engages in the development, production, and sale of food and nutrition products for infants, toddlers, children, and adults in North America and Israel. It offers baby snacks; baby feeding accessories, such as feeding bottles and teats; plant-based baby formula products; toddler, children, and adult nutrition products; and complementary food products. The company also offers its products through online. Else Nutrition Holdings Inc. is headquartered in Tel Aviv-Yafo, Israel.
How the Company Makes MoneyElse Nutrition generates revenue primarily through the sale of its plant-based infant formula and nutritional products. The company distributes its products through various channels, including online sales via its website and third-party e-commerce platforms, as well as retail partnerships with grocery stores and health food outlets. Key revenue streams include direct-to-consumer sales, wholesale distribution to retailers, and potential licensing agreements for its product formulations. Furthermore, strategic partnerships with distributors and collaborations with health professionals contribute to brand visibility and customer trust, enhancing sales growth.
Else Nutrition Holdings Inc Earnings Call Summary
Earnings Call Date:Sep 16, 2025
(Q2-2025)
| Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Neutral
Else Nutrition has shown significant progress in reducing costs and improving operational efficiency, with promising advancements in regulatory pathways and international growth. However, challenges such as revenue decline, negative gross margin, and inventory constraints have impacted performance.Q2-2025 Updates
Positive Updates
Expansion of Kids Ready-to-Drink Products
Else Nutrition's kids ready-to-drink products expanded to approximately 1,000 Walmart stores, showing significant market penetration and consumer interest.
Successful Cost Reductions
Operating expenses were reduced by almost 60% year-over-year, with wages falling by 50% and consulting fees by 90%.
Operating Loss Improvement
The operating loss improved by 55% to $1.4 million from $3.1 million in Q2 2024.
Regulatory Progress
Encouraging developments in U.S. legislation and recommendations from the National Academies provide confidence for a regulatory pathway for Else's plant-based infant formula.
International Growth
Toddler Signature products continue to perform well in Europe, with growing interest from distributors in key global markets.
Negative Updates
Revenue Decline
Total revenues for Q2 2025 were $1.5 million compared to $2.6 million in Q2 2024, mainly due to inventory constraints.
Negative Gross Margin
Gross profit for the quarter was a loss of $55,000, leading to a negative gross margin of minus 3.7%.
Out-of-Stock Situations
Inventory constraints led to more than $300,000 in lost sales, primarily in cereal products.
Challenges in the Canadian Market
Out-of-stock conditions in Canada, tied to cash priorities, reduced revenue from this region.
Net Loss
Net loss for the quarter was $1.4 million, although this was an improvement from $2.5 million in Q2 2024.
Company Guidance
During Else Nutrition's 2025 Second Quarter Conference Call, CEO Hamutal Yitzhak outlined several key metrics and strategic initiatives demonstrating the company's progress. The quarter saw total revenues of $1.5 million, a decrease from $2.6 million in Q2 2024, primarily due to inventory constraints and seasonal sales fluctuations. Gross profit faced a loss of $55,000, translating to a negative gross margin of -3.7%, affected by additional revenue reductions of CAD 270,000. Despite these challenges, operating expenses were significantly reduced by 60% year-over-year to $1.3 million, leading to a narrowed operating loss of $1.4 million, an improvement of 55% from the previous year. Else is targeting cash flow positivity by late 2026 or early 2027, focusing on supply chain optimization, regulatory advancements, and strategic partnerships to enhance growth and profitability.Else Nutrition Holdings Inc Financial Statement Overview
Summary
Else Nutrition Holdings Inc is facing significant financial challenges across all verticals. The income statement shows declining revenue and severe profitability issues. The balance sheet reflects high leverage and negative returns, while cash flow statements indicate difficulties in generating positive cash flow. The company needs to address these issues to improve its financial health and stability.Income Statement
Else Nutrition Holdings Inc has experienced declining revenue growth with a negative rate of -10.51% in the latest year. The company is facing significant challenges in profitability, as indicated by negative margins across the board: Gross Profit Margin (-70.79%), Net Profit Margin (-190.42%), EBIT Margin (-189.56%), and EBITDA Margin (-185.35%). These figures suggest a struggle to manage costs and generate profit from sales.25
Negative
Balance Sheet
The balance sheet shows a moderate Debt-to-Equity Ratio of 0.50, indicating a balanced approach to leveraging. However, the Return on Equity is significantly negative at -865.07%, reflecting substantial losses relative to shareholder equity. The Equity Ratio stands at 23.21%, suggesting a reasonable level of equity financing, but the overall financial health is weakened by persistent losses.40
Negative
Cash Flow
Cash flow analysis reveals a challenging situation with negative Free Cash Flow Growth of -24.22% and an Operating Cash Flow to Net Income Ratio of -1.56, indicating cash flow issues relative to net income. The Free Cash Flow to Net Income Ratio is slightly positive at 1.01, suggesting that free cash flow is marginally covering net income, but overall cash flow management remains a concern.30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.93M | 7.97M | 9.36M | 8.53M | 4.69M | 1.48M |
| Gross Profit | -1.93M | -5.64M | -85.00K | 1.31M | 743.00K | 498.00K |
| EBITDA | -12.61M | -14.78M | -15.17M | -17.12M | -17.15M | -8.82M |
| Net Income | -13.12M | -15.18M | -15.61M | -17.61M | -1.62M | -24.10M |
Balance Sheet | ||||||
| Total Assets | 6.37M | 7.56M | 16.07M | 26.16M | 32.92M | 29.32M |
| Cash, Cash Equivalents and Short-Term Investments | 215.00K | 103.00K | 4.92M | 15.38M | 24.28M | 24.71M |
| Total Debt | 1.12M | 874.00K | 3.09M | 3.37M | 941.00K | 228.00K |
| Total Liabilities | 6.80M | 5.80M | 9.35M | 10.57M | 6.15M | 18.11M |
| Stockholders Equity | -427.00K | 1.75M | 6.72M | 15.60M | 26.77M | 11.21M |
Cash Flow | ||||||
| Free Cash Flow | -7.50M | -9.12M | -18.31M | -21.07M | -16.05M | -9.82M |
| Operating Cash Flow | -7.50M | -9.06M | -18.31M | -20.91M | -15.76M | -9.59M |
| Investing Cash Flow | 1.88M | 2.71M | -1.13M | 170.00K | 1.14M | -3.93M |
| Financing Cash Flow | 5.05M | 3.73M | 7.44M | 11.69M | 16.85M | 32.45M |
Else Nutrition Holdings Inc Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Positive
0.02
Positive
Market Momentum
<0.01
Positive
48.25
Neutral
20.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BABY, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.25 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BABY.
Else Nutrition Holdings Inc Peers Comparison
Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
46 Neutral | $7.48M | ― | -2576.83% | ― | -22.92% | 39.22% | |
44 Neutral | 7.22M | -1.18 | ― | ― | -3.77% | -1.81% | |
33 Underperform | 1.87M | -0.27 | ― | ― | ― | -86.17% | |
27 Underperform | 5.30M | -2.85 | ― | ― | -96.63% | 32.78% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
* Consumer Defensive Sector Average
Performance Comparison
TSE:BABY
Else Nutrition Holdings Inc
0.02
-0.02
-42.86%
TSE:EMRG
Emergence Global Enterprises Inc
0.05
0.00
0.00%
PSYCF
Psyched Wellness
0.01
0.00
0.00%
TSE:MOOO
Happy Supplements Inc.
0.14
-1.31
-90.34%
TSE:CULT
Cult Food Science Corp.
0.02
-0.04
-66.67%
TSE:PNGA
Pangea Natural Food, Inc.
0.36
0.15
71.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.